Gemcitabine in first-line therapy of locally advanced and/or metastatic non-small cell lung cancer (NSCLC): Review of the results of randomized phase III studies;Gemcitabin in der first-line-therapie des lokal fortgeschrittenen und metastasierten nicht-kleinzelligen bronchialkarzinoms (NSCLC): Ergebnisübersicht randomisierter phase-III-studien

Onkologie

Volumn 28, Issue SUPPL. 1, 2005, Pages 1-28

  Leschinger, Monika I ^a   Helsberg, Karin ^a   Langer, Frank ^a   Schuette, Wolfgang H W ^b  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b Städtisches Krankenhaus Marthe Maria   (Germany)

Author keywords

Chemotherapy; First line therapy; Gemcitabine; NSCLC; Phase III study

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PRINOMASTAT; TAXANE DERIVATIVE; VINBLASTINE; VINDESINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACNE; ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; EDEMA; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PHLEBITIS; RASH; REVIEW; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; FEMALE; HOSPITALIZATION; LUNG TUMOR; MALE; METASTASIS; MORTALITY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17844391514     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084364     Document Type: Review

References (93)

1. Alberola V, Camps C, Provencio M, Isla D, Rosell R, et al.; Spanish Lung Cancer Group: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003;21:3207-3213.
2. Berardi R, Porfiri E, Massidda B, Labianc R, Cetto G, et al.: Gemcitabine (GEM) and cisplatin (PL) versus gemcitabine alone in stage IV non small cell lung cancer (NSCLC): Preliminary results of RA randomized multicenter phase III study. Proc Am Soc Clin Oncol 2001;abstr 1385.
3. Bissett D, von Pawel J, Mercier R, Price A, Nicolson M, et al. on behalf of the AG3340-017 Study Investigators: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002;abstr 1183.
4. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, et al.: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:12-18.
5. Comelia P, Frasci G, Panza N, Manzione L, De Cataldis G, et al.: Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000;18:1451-1457.
6. Comella P: Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group. Oncology (Huntingt) 2000;14:35-40.
7. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, et al.: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17: 3522-3530.
8. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, et al. for the TALENT Study Investigators: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22(suppl 14S);abstr 7010.
9. Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, et al.; Gruppo Ocologico Italia Meridionale: Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vi-norelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003;39:179-189.
10. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
11. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, et al.: Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-3034.
12. Kim JH, Kim SY, Jung KH, Park K, Suh CW, et al.: Randomized phase 3 study of gemcitabine plus cisplatin versus etoposide plus cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. ESMO 2002. Ann Oncol 2002;13(suppl 5):42;abstr 518P
13. Krzakowski M, Wenczl M, Brodowicz T, Tzekova V, Ramlau R, et al.: Gemcitabine and cisplatin (GC) +/_ subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG). Oral Presentation at ASCO Annual Meeting 2004. Proc Am Soc Clin Oncol 2004; abstr 7067.
14. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, et al.: The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2004; 22(suppl 14);abstr 7006.
15. Martoni A, Marino A, Sperandi F, Giaquinta S, Preti P, et al.: Multicenter randomized clinical trial of cisplatin (CP)+ vinorelbine (VNR) vs CP+gemcitabine (GEM) in advanced NSCLC: Results of the first analysis. Proc Am Soc Clin Oncol 2003;22;abstr 2512.
16. Melo MJ, Barradas P, Costa A, Cristovao M, Alves P: Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): Mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Oral presentation at ASCO Annual Meeting 2002, abstr 1205.
17. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, et al.: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
18. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, et al.; Italian Lung Cancer Project: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
19. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al.; Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;10:92-98.
20. Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, et al.; European Lung Cancer Working Party: A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002;13:874-882.
21. Van Meerbeeck JP, Smit EF, Lianes P, Schramel F, Lenz MA, et al., EORTC-Lung Cancer Group: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Oral presentation at ASCO Annual Meeting 2001, abstr 1228.
22. Giaccone G; European Organization for Research and Treatment of Cancer Group: Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975. Semin Oncol 2002;29(suppl 9):47-49.
23. Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, et al.: First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: A phase III trial. Br J Cancer 2003;89:1192-1199.
24. Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, et al.: Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003;98: 542-553.
25. Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E: Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: A phase III randomised trial. Lung Cancer 2002;37:9-14.
26. Rudd RM, Gower NH, James LE, Gregory W, Eisen T, et al.: Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Oral presentation at ASCO Annual Meeting 2002, abstr 1164.
27. Sederholm C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A phase III study by the Swedish Lung Cancer Study Group (SLUSG). Oral presentation at ASCO Annual Meeting 2002, abstr 1162.
28. Treat J, Belani CP, Edelman M, Socinski M, Gonin R, et al.: A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22:624;abstr 2511.
29. Zatloukal P, Petruzelka L, Zemanova M, Kolek V, Skrickova J, et al.: Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003;41:321-331.
30. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, et al.; Greek Oncology Cooperative Group (GOCG) for Lung Cancer: Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A randomised multicentre trial. Lancet 2001;357:1478-1484.
31. Kakolyris S, Tsiafaki X, Agelidou A, Arapis J, Boukovinas J, et al.: Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer. Poster presented at ASCO Annual Meeting 2002, abstr 1182.
32. Pujol JL, Breton JL, Riviere A, Rebattu P, Depierre A, et al.: Gemcitabine-docetaxel (GD) versus vinorelbine-cisplatin (VC) in advanced non-small cell lung cancer (NSCLC). A phase III study. Lung Cancer 2003;41 (suppl 2)S65; abstr O-222.
33. Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, et al.: Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004;91:489-497.
34. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 2002;20:3578-3585.
35. Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, et al.: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529-2536.
36. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, et al.; MILES Investigators: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95: 362-372.
37. Laack E, Dickgreber N, Muller T, Knuth A, Benk J, et al.; German and Swiss Lung Cancer Study Group: Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: From the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004;22:2348-2356.
38. Abratt RP, Szczesna A, Mattson K, Wernli M, Reiterer P, et al.: Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis. J Clin Oncol 2004; 22(suppl 14);abstr 7016.
39. Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, et al.; Leuven Lung Cancer Group: Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 2001;12:1221-1230.
40. Le Chevalier T, Brown A, Natale R, Scagliotti G, Vansteenkiste J, et al.: Gemcitabine in the treatment of mon-small cell lung cancer (NSCLC): A meta-analysis of survival and progression-free survival data. Lung Cancer 2003;41(suppl 2):70.
41. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, et al.: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005, in Druck.
42. Statistisches Bundesamt (Hrsg): Gesundheitsbericht für Deutschland, 1998, Kurzfassung. Gesundheitsberichtserstattung des Bundes. Statistisches Bundesamt, 1998.
43. Statistisches Bundesamt (Hrsg): Lungenkrebs ist fünfthäufigste Todesursache. Pressemitteilung vom 7. Juni 2004. Statistisches Bundesamt, Zweigstelle Bonn.
44. Statistisches Bundesamt (Hrsg): Todesursachenstatistik 1968 bis 1997. Statistisches Bundesamt, Zweigstelle Bonn, 1999.
45. Levi F, Lucchini F, La Vecchia C, Negri E: Trends in mortality from lung cancer in the European Union 1955-1994. Lancet 1999;354:742-743.
46. Novello S, Le Chevalier T: Chemotherapy for non-small-cell lung cancer. Part 1: Early stage disease. Oncology (Huntington) 2003;17:357-364.
47. Cochrane Group: Chemotherapy for non-small cell lung cancer. Non-small Cell Lung Cancer Collaborative Group. Cochrane Database of Systematic Reviews 2000 (2):CD002139.
48. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, et al.: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999; 17:3188-3194.
49. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24:17-24.
50. Helsing M, Bergman B, Thaning L, Hero U: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 1998;34:1036-1044.
51. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, et al.: American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004;22:330-353.
52. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, et al.: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 2004;292: 470-484.
53. Lilenbaum RC, Herndon J, List M, Desch C, Watson D, et al.: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 2002;abstr 2.
54. Souquet PJ, Tan EH, Rodrigues Pereira J, Van Klaveren R, Price A, et al.: GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002;13:1853-1861.
55. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, et al.: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
56. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
57. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, et al.: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
58. Langer CJ, Vangel M, Schiller J, Harrington DP, Sandler A, et al.: Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003;22: 639;abstr 2571.
59. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003;98: 779-788.
60. Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews. BMJ 1998;317:771-775.
61. Manegold C: Gemcitabine (Gemzar) in non-small cell lung cancer. Expert Rev Anticancer Ther 2004;4:345-360.
62. Scagliotti GV, Novello S: Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer. Lung Cancer 2002;38(suppl 2):S13-19.
63. Noble S, Goa KL: Gemcitabine - a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54:447-472.
64. Storniolo AM, Allerheiligen SR, Pearce HL: Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 1997;24(suppl 7):S2-S7.
65. Peters GJ, Ruiz van Haperen VW, Bergman AM, Veerman G, Smitskamp-Wilms E, et al.: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996;23(suppl 10):S16-S24.
66. Comella P; Southern Italy Cooperative Oncology Group: Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001;28(suppl 7):7-10.
67. Wolf M, Gatzemeier U, Niedernele N: Therapie des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms. Onkologe 2002;8:471-486.
68. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, et al.: Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996;32A:243-248.
69. Martin C, Lund B, Anderson H, Thatcher N: Gemcitabine: Once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 1996;7: 351-357.
70. Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer J-P: Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004;18:85-91.
71. Carrato A, Garcia-Gomez J, Alberola V, Massuti BJ, Sanchez J, et al.: Carboplatin (CARBO) in combination with gemcitabine (GEM) in advanced non-small cell lung cancer (NSCLC). Comparison of two consecutive phase II trials using different schedules. Proc Am Soc Clin Oncol 1999;abstr 1922.
72. Deutsche Krebsgesellschaft, Junginger T (Hrsg): Kurzgefasste interdisziplinäre Leitlinien 2002. Diagnose und Therapie maligner Erkrankungen, ed 3. Germering, Zuckschwerdt, 2002.
73. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, et al.: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 1997;24(suppl 7):S7-S55.
74. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, et al.: Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 2001;19:1064-1070.
75. Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, et al.; MILES Investigators: Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001;31:277-284.
76. Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, et al.: Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study. Lung Cancer 2000;27:75-80.
77. Altavilla G, Adamo V, Buemi B, Marabello G, Maisano R, et al.: Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer. Anticancer Res 2000;20:3675-3678.
78. Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, et al.: Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003;41:81-89.
79. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS: Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-3223.
80. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS: Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′- deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-872.
81. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, et al.: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198.
82. Scalliet P, Goor C, Galdermans D, van Meerbeek J, Groen HJ, et al.: Gemzar (gemcitabine) with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;abstr 1923.
83. Van Putten JW, Price A, van der Leest AH, Gregor A, Little FA, et al.: A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9: 2472-7247.
84. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, et al.: International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;22;350: 351-360.
85. Winton TL, Livingston R, Johnson D, Rigas J, Cormier Y, et al., National Cancer Institute of Canada: A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC). Intergroup JBR.10. J Clin Oncol, 2004;22(suppl 14S);abstr 7018.
86. Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, et al., for CALGB, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004;22(suppl 14S);abstr 701.
87. Hamada C, Ohta M, Wada H, Fujimura S, Kodama K, et al.: Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 2004;22(suppl 14S);abstr 7002.
88. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, et al.; French Thoracic Cooperative Group: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
89. Rosell R, Gomez-Codina J, Camps C, Javier Sanchez J, Maestre J, et al.: Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26: 7-14.
90. Shepherd FA, Johnston MR, Payne D, Burkes R, Deslauriers J, et al.: Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Br J Cancer 1998; 78:683-685.
91. Cappuzzo F, Bartolini S, Calandri C, Crino L: Induction therapy for early-stage non-small-cell lung cancer. Oncology (Huntingt) 2004;18(suppl 5):32-37.
92. Rosell R, Felip E, Maestre J, Sanchez JM, Sanchez JJ, et al.: The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer 2001;34(suppl 3):S63-S74.
93. Van Zandwijk N, Smit EF, Kramer GW, Schramel F, Gans S, et al.: Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658-2664.